ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join us for the ACC Rockies Chapter Meeting from September 8-9, 2023 at the Hyatt Centric in Park City, Utah. For more information and to register, please visit: https://web.cvent.com/event/314c67f2-d26f-4ad9-bfd7-8011b1bd9dcb/summary
Latest in Cardiology from ACC.org
- Comparative Outcomes of Empagliflozin to Dapagliflozin in HF PatientsAre there differences between empagliflozin and dapagliflozin for the composite outcome of all-cause mortality and hospitalization in patients with heart failure (HF)?
- Small Left Ventricle in AF Patients and Increased CV RiskWhat is the association between small left ventricle (LV) and risk of cardiovascular (CV) events in the atrial fibrillation (AF) population?
- Transcatheter-Based Interventions for Tetralogy of Fallot: Key PointsThe following are key points to remember from a state-of-the-art review on transcatheter-based interventions for tetralogy of Fallot (TOF) across all age groups:
- Discordance Among ApoB, non–HDL-C, and Triglycerides for CV PreventionDoes apolipoprotein B (apoB) have a utility in atherosclerotic cardiovascular disease (ASCVD) or are low-density lipoprotein cholesterol (LDL-C), non–high-density lipoprotein cholesterol (non–HDL-C), and triglycerides sufficient for routine cardiovascular (CV) care?
- Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-3The goal of the STOPDAPT-3 trial was to compare the safety and efficacy of an aspirin-free strategy among patients undergoing percutaneous coronary intervention (PCI) or at high bleeding risk.